 Iovance Biotherapeutics focuses on developing treatments for cancers, a market with minimal supply and large demand. The company recently received approval to proceed with further investigations into a revolutionary new treatment for NSCLCs. The company relies on smart partnerships for research and development to avoid accruing excess debt. Iovance has no viable products on the market to date, which means they generate no revenue or profit, which adds significant risk to investment. 